Analysts expect that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will report ($0.46) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Idera Pharmaceuticals’ earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.53). Idera Pharmaceuticals posted earnings per share of ($0.80) during the same quarter last year, which indicates a positive year over year growth rate of 42.5%. The company is scheduled to issue its next earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that Idera Pharmaceuticals will report full-year earnings of ($1.89) per share for the current fiscal year, with EPS estimates ranging from ($2.49) to ($1.37). For the next financial year, analysts anticipate that the business will report earnings of ($1.83) per share, with EPS estimates ranging from ($2.58) to ($1.33). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Idera Pharmaceuticals.
Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.12 million. Idera Pharmaceuticals had a negative net margin of 9,045.47% and a negative return on equity of 75.10%.
Several brokerages recently commented on IDRA. Zacks Investment Research downgraded shares of Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. ValuEngine upgraded shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. HC Wainwright dropped their target price on shares of Idera Pharmaceuticals to $14.00 and set a “buy” rating on the stock in a report on Friday, March 8th. Finally, Wedbush set a $7.00 target price on shares of Idera Pharmaceuticals and gave the stock an “outperform” rating in a report on Thursday, March 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Idera Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $16.71.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Deutsche Bank AG raised its stake in shares of Idera Pharmaceuticals by 45.3% in the fourth quarter. Deutsche Bank AG now owns 55,548 shares of the biotechnology company’s stock worth $153,000 after acquiring an additional 17,306 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Idera Pharmaceuticals by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 230,577 shares of the biotechnology company’s stock worth $638,000 after acquiring an additional 8,468 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Idera Pharmaceuticals in the fourth quarter worth about $61,000. Millennium Management LLC raised its stake in shares of Idera Pharmaceuticals by 36.1% in the fourth quarter. Millennium Management LLC now owns 602,639 shares of the biotechnology company’s stock worth $1,669,000 after acquiring an additional 159,916 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Idera Pharmaceuticals in the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.
Shares of IDRA opened at $2.62 on Friday. Idera Pharmaceuticals has a one year low of $2.25 and a one year high of $17.12.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.
Featured Story: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.